🇺🇸 Remimazolam Tosilate for Injection in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1
Most-reported reactions
- Shock — 1 report (100%)
Frequently asked questions
Is Remimazolam Tosilate for Injection approved in United States?
Remimazolam Tosilate for Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Remimazolam Tosilate for Injection in United States?
Jiangsu HengRui Medicine Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.